𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice

✍ Scribed by S. S. LEE; V. G. BAIN; K. PELTEKIAN; M. KRAJDEN; E. M. YOSHIDA; M. DESCHENES; J. HEATHCOTE; R. J. BAILEY; S. SIMONYI; M. SHERMAN; THE CANADIAN PEGASYS STUDY GROUP

Book ID
118699864
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
217 KB
Volume
23
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Response to pegylated interferon alfa-2a
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4
✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 ¡g/week) plus ribavirin (β‰₯11 mg/kg/day)

Association of host pharmacodynamic effe
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C
✍ Raymond T. Chung; Fred F. Poordad; Tarek Hassanein; Xiaolei Zhou; Ellen Lentz; A πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 773 KB

Patients receiving therapy for chronic hepatitis C virus (HCV) infection frequently experience cytopenias and weight loss. We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic par